Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sosei, Morphochem to Develop New Telomerase Inhibitor
April 2, 2001
- Industry FTC to Prohibit Financial Support for Social Gatherings at Medical Institutions
April 2, 2001
- Sankyo, Metabasis Agree to Continue Codevelopment of Antidiabetic Drug
April 2, 2001
- Sales of Relenza, Tamiflu Far Below Expectations
April 2, 2001
- Korosho to Start DRG Trial in April
April 2, 2001
- WORLD NEWS IN BRIEF
April 2, 2001
- Most municipal Hospitals Have Anti-Accident Manuals: JMHA Survey
April 2, 2001
- Major Japanese firms Aiming at 20% of Total Sales Overseas in 2005: JPMA Report
April 2, 2001
- MRSA Infections Found in 0.55% of Inpatients: Korosho Survey
April 2, 2001
- Final Draft of Ethical Guidelines for Human Genome Research Approved
April 2, 2001
- Sankyo Ties Up with Menarini to Market CS-866 in Europe
April 2, 2001
- 'Number System' Proposed for Social Security
April 2, 2001
- Celera to Acquire Minority Interest in HuBit Genomix
April 2, 2001
- Radicut, Herceptin, Zyvox Approved by CDFS
April 2, 2001
- DIAGNOSTIC NEWS IN BRIEF
April 2, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
April 2, 2001
- AIN PHARMACIEZ Issues Membership Cards
April 2, 2001
- 18.6% of Inpatients Can Be Discharged: Survey
April 2, 2001
- Sales of OTC Drugs in FY2000 Likely to Drop Due to Poor Prevalence of Flu
April 2, 2001
- Percentage of Deficit-ridden Hospitals Declines Slightly: NHFJ Survey
April 2, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…